Vaccine Adjuvants Market Information: By Type (Pathogen Components, Particulate Adjuvants, others), By Route of Administration (Oral, Intramuscular, Subcutaneous, and Intradermal), and By End Users (Pediatric, Adult) – Global Forecast Till 2023
Vaccine adjuvant is an immunological agent that is added to the vaccine to provide long-lasting protection against antigen and enhance the immune response. Vaccine adjuvant can modify the effect of other agents. A new report on the global vaccine adjuvants market, published by Market Research Future (MRFR), anticipates that this market could oversee advancement at 10.1% CAGR between 2017 and 2023.
The most important market driver for the global vaccine adjuvants market growth is governments’ initiatives for vaccinations. The high prevalence of infectious and zoonotic diseases is also leading the market to grow. Other factors contributing to the market growth include growing focus on improved as well as long-lasting immunization against existing and emerging diseases, increasing investments by companies in research & development (R&D), increasing demand for vaccines, increasing prevalence of the diseases in children, increasing focus on immunization programs, and rising number of awareness programs to promote vaccination. However, cost of developing a new vaccine adjuvants and high toxicity of adjuvants can hinder the market growth.
Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/1098
The global vaccine adjuvants market segmentation encompasses types of end-users, routes of administration, and types. MRFR’s take on the market surveys various facets of the market in-depth.
Based on end-users, this market has been segmented into pediatric and adult. Regarding routes of administration, the market has been segmented into oral, intradermal, intramuscular, and subcutaneous. By types, the market has been segmented into particulate adjuvants, pathogen components, and others.
A geographical outlining of the global vaccine adjuvants market covers the Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA).
The Americas is the largest regional market as North America alone holds the potential of being the largest regional market. Due to technological advancement and presence of key market players, North America is a greater market than South America. In the Americas, the market is strong due to favorable conditions for R&D, and extensive use of the vaccine to prevent communicable and non-communicable diseases.
Europe is the second-largest regional market followed by Asia Pacific due to availability of funds for R&D activities, and growing initiatives taken by the government and non-government organizations (NGOs) for diseases preventive measures. The most powerful country-specific markets in Western Europe are France, Germany, Italy, Spain, and the UK.
During the forecast period, the Asia Pacific market can be the fastest growing regional market due to increasing prevalence of communicable diseases. Due to the high density of population and improving the healthcare sector, China and India are rising as important country-specific markets in this region. Other similar markets are Australia, Japan, and South Korea.
In the MEA region, the market is low due to lack of awareness, less emphasis on R&D activities, and poor medical facilities. Some country-specific markets that are better than most of the markets are Kuwait, Oman, Qatar, Saudi Arabia, and UAE. A valuation of the remaining countries in the MEA region featured in this report anticipates a decent contribution to market revenue from some other countries.
Big players in the global vaccine adjuvants market include Adjuvatis (France), Agenus Inc. (USA), Aphios Corporation (USA), Avanti Polar Lipids Inc. (USA), Brenntag Biosector (Denmark), CureVac AG (Germany), CSL Limited (Australia), Invivogen (USA), MPV Technologies (USA), Novavax Inc.(USA), OZ Biosciences (France), SEPPIC (France), SPI Pharma Inc. (USA), Sergeant Adjuvants (USA), Sigma-Aldrich Co. LLC. (India), Vaxine Pty Ltd (Australia), VaxLiant LLC. (USA), and Viscogel AB (Sweden).
Latest Industry News
12 AUG 2019: An Industry-Academia Collaborative Mission of Department of Biotechnology for accelerating early Development for Biopharmaceuticals called National Biopharma Mission (NBM) is being implemented by Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking of Department of Biotechnology (DBT). The implementation is meant to create an ecosystem for innovative indigenous product development by Indian researchers, startups and Small & Medium Enterprises (SMEs) to make Indian biotech industry, globally competitive.
Table Of Contents
1 Report Prologue
2 Market Introduction
2.2 Scope Of Study
2.3 Research Objective
2.4 Assumptions & Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
5 Market Factor Analysis
Get access to full summary @ https://www.marketresearchfuture.com/reports/vaccine-adjuvants-market-1098
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312